Skip to Main Content

Author Details

Patrick Van Dreden
Institut Universitaire de Cancerologie (IUC), Sorbonne Universite
1985
84
22
PMIDPaper TitleJournal TitlePublished Year
36894870Potential utility of a multi-component coagulation factor panel to calculate MELD scores and assess the risk of portal vein thrombosis in chronic liver disease.BMC Gastroenterol2023
37497426Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale.TH Open2023
35870325The procoagulant phospholipid dependent clotting time and the initiation phase of thrombin generation test are mandatory for the evaluation of the risk for severe early onset preeclampsia.Thromb Res2022
35733370Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms.Clin Appl Thromb Hemost2022
35498378Public Awareness on Cancer-Associated Thrombosis among the Greek Population: First Findings from the ROADMAP-CAT Awareness Study.TH Open2022
35483884Perioperative Coagulation Profile in Major Liver Resection for Cancer: A Prospective Observational Study.Thromb Haemost2022
36428852High Plasma Levels of Activated Factor VII-Antithrombin Complex Point to Increased Tissue Factor Expression in Patients with SARS-CoV-2 Pneumonia: A Potential Link with COVID-19 Prothrombotic Diathesis.Diagnostics (Basel)2022
36555812PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells.Int J Mol Sci2022
33946120SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia.Thromb Haemost2021
34912886Endothelial dysfunction and hypercoagulability in severe sickle-cell acute chest syndrome.ERJ Open Res2021
34689575Combined Vaccination Approaches for COVID-19. Will These Improve the Efficacy Spectrum?Clin Appl Thromb Hemost2021
34187132The high frequency of anti-PF4/heparin antibodies in patients with COVID-19 is neither related to heparin treatment or to an increased incidence of thrombosis.Clin Chem Lab Med2021
31583746Different sensitivity of von Clauss reagents for the diagnosis of dysfibrinogenemia.Eur J Haematol2020
32006891Extracellular vesicles derived from pancreatic cancer cells BXPC3 or breast cancer cells MCF7 induce a permanent procoagulant shift to endothelial cells.Thromb Res2020
33284037Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients With Severe Coronary Artery Disease. The ROADMAP-CAD Study.Clin Appl Thromb Hemost2020
32736779Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer.Thromb Res2020
32961572Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19.Thromb Haemost2020
32920811Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine.Thromb Haemost2020
31693008Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process.TH Open2019
28681632Graft Product for Autologous Peripheral Blood Stem Cell Transplantation Enhances Thrombin Generation and Expresses Procoagulant Microparticles and Tissue Factor.Clin Appl Thromb Hemost2018
30104289Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.Oncologist2018
30405097Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.Blood Cancer J2018
30349889Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots.Res Pract Thromb Haemost2018
28854808Thrombin Generation Profile in Patients With Steady State Peripheral Arterial Disease.Clin Appl Thromb Hemost2018
27609342The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.Clin Appl Thromb Hemost2017
28360822Impact of blood hypercoagulability on in vitro fertilization outcomes: a prospective longitudinal observational study.Thromb J2017
29604900The Role of Tissue Factor in Cancer-Related Hypercoagulability, Tumor Growth, Angiogenesis and Metastasis and Future Therapeutic Strategies.Crit Rev Oncog2017
29075792Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer.Int J Oncol2017
29075790Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.Int J Oncol2017
26967388Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma.Oncotarget2016
26632514Decreased levels of procoagulant phospholipids in bleeding patients treated by vitamin K antagonists.Thromb Res2016
27664390Transient Factor V deficiency associated with Factor V-immunoglobulin complexes but without evidence of a classical inhibitor.Thromb Res2016
27553758HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease.J Neuroinflammation2016
27161741PO-53 - Prospective evaluation of risk assessment models and biological markers of hypercoagulability for the identification of high VTE risk patients with lung adenocarcinoma. The ROADMAP study.Thromb Res2016
27161675OC-03 - Modelisation of the procoagulant properties of cancer cells and their capacity to alter the antithrombotic efficiency of LMWHs and specific inhibitors of factor Xa.Thromb Res2016
25963480Levels of Alternatively Spliced Tissue Factor in the Plasma of Patients with Pancreatic Cancer May Help Predict Aggressive Tumor Phenotype.Ann Surg Oncol2015
26489727Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.Thromb Res2015
26023170Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay.Clin Appl Thromb Hemost2015
22724467Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3.Curr Vasc Pharmacol2014
25535397Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.BMC Cancer2014
25204998Isolated decrease in factor V in children treated by 6-Mercaptopurine for acute lymphoblastic Leukemia.Thromb Res2014
24696689Procoagulant phospholipids and tissue factor activity in cerebrospinal fluid from patients with intracerebral haemorrhage.Adv Hematol2014
24383845Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics.Br J Haematol2014
23096108Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure.Clin Chem Lab Med2013
24094602Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma.Thromb Res2013
21880353Comparative evaluation of Tissue factor and Thrombomodulin activity changes during normal and idiopathic early and late foetal loss: the cause of hypercoagulability?Thromb Res2012
22535498The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.Thromb Haemost2012
22551976Decreased procoagulant phospholipids in patients treated by vitamin K antagonists.Thromb Res2012
21917301Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7.Thromb Res2012
21507465Decreased activity of soluble thrombomodulin and plasma procoagulant phospholipids in childhood bone marrow transplantation with severe complications.Thromb Res2011
  • 1 - 50 of 84

Recommended Authors

Kimberly A Thomas
Washington University in St. Louis School of Medicine
Career Start Year 2011
Number of shared co-authors 0
Jay S Raval
University of New Mexico
Career Start Year 2006
Number of shared co-authors 1
Benjamin F Tillman
Vanderbilt University Medical Center
Career Start Year 2006
Number of shared co-authors 1
Matthew D Neal
University of Pittsburgh Medical Center
Career Start Year 2004
Number of shared co-authors 0
Trung C Nguyen
Texas Children's Hospital Baylor College of Medicine
Career Start Year 2001
Number of shared co-authors 2
Anjali Sharathkumar
Carver College of Medicine, University of Iowa
Career Start Year 1999
Number of shared co-authors 0
Ian J Welsby
Duke University School of Medicine
Career Start Year 1999
Number of shared co-authors 0
Nicole D Zantek
University of Minnesota
Career Start Year 1999
Number of shared co-authors 0
Andrew Eisenberger
NewYork-Presbyterian/Columbia University Irving Medical Center
Career Start Year 1997
Number of shared co-authors 0
Alfred I Lee
Yale University School of Medicine
Career Start Year 1996
Number of shared co-authors 0
Pampee P Young
Vanderbilt University Medical Center
Career Start Year 1996
Number of shared co-authors 0
Achim Obergfell
Novartis Pharma
Career Start Year 1995
Number of shared co-authors 2
Paul Monagle
Kids Cancer Centre, Sydney Children's Hospital
Career Start Year 1995
Number of shared co-authors 0
Thomas J Raife
University of Wisconsin School of Medicine and Public Health
Career Start Year 1994
Number of shared co-authors 0
Bego??a Campos
The University of Cincinnati
Career Start Year 1994
Number of shared co-authors 2
Marc Zumberg
University of Florida
Career Start Year 1993
Number of shared co-authors 0
Ulrike M Reiss
Hospital
Career Start Year 1992
Number of shared co-authors 0
Jeffrey L Winters
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 0
Bruce S Sachais
Clinical Services
Career Start Year 1991
Number of shared co-authors 0
Thomas G DeLoughery
Oregon Health & Science University
Career Start Year 1990
Number of shared co-authors 0
Andrew D Mumford
University of Bristol
Career Start Year 1989
Number of shared co-authors 0
John A Heit
Mayo Clinic
Career Start Year 1988
Number of shared co-authors 0
Jane E Freedman
Vanderbilt University Medical Center
Career Start Year 1986
Number of shared co-authors 0
Robert I Parker
Stony Brook Renaissances School of Medicine, Stony Brook University
Career Start Year 1984
Number of shared co-authors 0
Henry M Rinder
Yale School of Medicine
Career Start Year 1984
Number of shared co-authors 0
Thomas L Ortel
Duke University Medical Center
Career Start Year 1983
Number of shared co-authors 0
Jerrold H Levy
Duke University Hospital, Duke University School of Medicine
Career Start Year 1982
Number of shared co-authors 0
Steven A Krilis
University of NSW
Career Start Year 1979
Number of shared co-authors 0
Eric F Grabowski
Massachusetts General Hospital
Career Start Year 1970
Number of shared co-authors 0
David Ginsburg
University of Michigan ann arbor
Career Start Year 1965
Number of shared co-authors 0

Collaborators

Barry Woodhams
Haemacon Ltd
Co-authored papers 9
Mariette Adam
Co-authored papers 3
Rémi Favier
Co-authored papers 3
Vladimir Y Bogdanov
University of Cincinnati College of Medicine
Co-authored papers 3
Dusten Unruh
Feinberg School of Medicine, Northwestern University
Co-authored papers 2
Syed A Ahmad
University of Cincinnati College of Medicine
Co-authored papers 2
Kimberly W Hart
Vanderbilt University Medical Center
Co-authored papers 1
Christopher J Lindsell
Duke University
Co-authored papers 1
Changchun Xie
University of Cincinnati
Co-authored papers 1
Nicola Martinelli
Co-authored papers 1
Oliviero Olivieri
Co-authored papers 1
Farah Sagin
Co-authored papers 1
Tiffany Pascreau
Co-authored papers 1
Domenico Girelli
Co-authored papers 1
Release 1.2